Next 10 |
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...
Merger activity remained unchanged last week with two new deals announced and seven deals closing. Deal Statistics: New Deals: The acquisition of Alder BioPharmaceuticals (ALDR) by H. Lundbeck A/S for $1.95 billion. Under the terms of the agreement, Alder stockholders will be of...
NEW YORK, NY / ACCESSWIRE / September 20, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Cambrex Corporation ( CBM ) ("Cambrex")...
Monday was a poor day for the major benchmarks, as market participants reacted negatively to news from the Middle East. A drone attack on oil production facilities in Saudi Arabia sent shockwaves across the global economy, and many now fear that higher energy prices could further slow economic...
ALDR stock is the biggest gainer in the biotech space on the news that H. Lundbeck A/S will acquire Alder BioPharmaceuticals Inc (NASDAQ:ALDR) for $2 billion. Solid Boost for Shareholders When it comes to the biggest pharmaceutical companies in the world, then it is a well-known fact th...
Gainers: Alder BioPharmaceuticals (NASDAQ: ALDR ) +84% . SemGroup Corporation (NYSE: SEMG ) +63% . Yuma Energy (NYSEMKT: YUMA ) +63% . Wins Finance Holdings (NASDAQ: WINS ) +55% . Whiting Petroleum Corporation (NYSE: WLL ) +43% . New Concept Energy (NYSEMKT: GBR ) +34% . Califo...
News, Short Squeeze, Breakout and More Instantly...
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...